Action 0VY I-MAB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues I-Mab Börse Stuttgart

Actions

0VY

US44975P1030

Temps Différé Börse Stuttgart
Autres places de cotation
 08:04:48 05/07/2024 		Varia. 5j. Varia. 1 janv.
1,42 EUR 0,00% Graphique intraday de I-Mab -11,25% -12,88%
06/06 I-Mab nomme Phillip Dennis au poste de directeur médical CI
05/06 I-Mab collabore avec Bristol-Myers pour évaluer le givastomig dans une étude de combinaison pour les cancers de l'estomac et de l'œsophage MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab Appoints Phillip Dennis as Chief Medical Officer
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
I-Mab to Participate at the Jefferies Global Healthcare Conference
I-MAB Filed 2023 Annual Report on Form 20-F
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.
Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023.
Verastem Names John Hayslip as Chief Medical Officer
I-Mab Announces Chief Medical Officer Changes
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
I-Mab Completes Business Divestiture in China
I-Mab Announces Closing of the Divestiture of Business Operations in China
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.
I Mab : Resignations of Director and Senior Management - Form 6-K
I-Mab Announces Executive Resignation
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IMAB
  4. Action 0VY
  5. Actualités I-Mab
  6. Autres langues